Buscar
Mostrando ítems 1-10 de 258
Pharmacoeconomics, Outcomes Research, Health Technology Assessment, Comparative Effectiveness, Patient Centered Outcomes Research in Latin America 2016: brief update
(Elsevier Inc, 2016-12)
One more year has elapsed since our last issue of VIHRI focused on Latin America (LA). It has been a very active year in our field in LA. Though in even years there is no regional ISPOR meeting, and we wait for the one to ...
To circ or not to circ: clinical and pharmacoeconomic outcomes of a prospective trial of topical steroid versus primary circumcision
(Sociedade Brasileira de Urologia, 2010-02-01)
PURPOSE: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeconomic protocol. MATERIALS AND METHODS: We treated 59 patients (3-10 years of age) randomized into two groups: ...
On the need of pharmacoeconomics. Beginning by the principles
Health expenditures and medication usage have increased dramatically in last years, situation that alerts governments and health authorities, and than can be related with some facts: not standardized medical prescription, ...
Pharmacoeconomy: an indispensable tool for the rationalization of health costs
(Universidade de São Paulo, Faculdade de Ciências Farmacêuticas, 2011)
Due to the considerable increase in public expenditure with health issues, mainly regarding drugs, several countries, including Australia and England, have already implemented, or are in the process of discussing the ...
Farmacoepidemiologia no Brasil: uma revisão bibliográfica
(Universidade Federal do Rio Grande do NorteBrasilUFRNBiomedicina, 2017-12-08)
Medicines consist of an important therapeutic tool of numerous diseases and is related to the generation of quality of life of the patient. The present study aims to describe the current scenario of pharmacoepidemiological ...
Analysis of extemporaneous oral liquid from commercially available drugs in hospital
(2016-07-01)
The objective of this study was to identify drugs that received dose adjustments (DA) and pharmaceutical alternatives (PA) that avoid DA, and calculate the economic percentage of this replacement. A descriptive, observational ...